Seeking Alpha

blackhawk465

blackhawk465
Send Message
View as an RSS Feed
View blackhawk465's Comments BY TICKER:
Latest  |  Highest rated
  • The Trouble May Just Be Starting For Wynn Resorts [View article]
    Hi Daniel,

    Thank you for your response. Please kindly provide the link that you reference about authoring articles on the casino stocks near there 52 week highs, otherwise you lose all credibility.
    Subsequently can you definitively state that no friends, family or business associates are shorting casino stocks that you are writing about with such passion on a daily basis?
    Thank you in advance Daniel..
    Apr 1, 2015. 02:05 PM | 3 Likes Like |Link to Comment
  • The Trouble May Just Be Starting For Wynn Resorts [View article]
    Hi Daniel,

    Thank you kindly for your reply and comments. If you did author an article(s) recommending selling the casino stocks near there 52 week highs please kindly provide the link to the article, otherwise you lose all credibility as an author and or a fund manager.
    Certainly you would not be the first hedge fund person to shill for "friends" that are shorting these stocks.
    Can you definitively state that no one associated or related to you is shorting these same casino stocks?
    Thank you in advance..
    Apr 1, 2015. 01:07 PM | 2 Likes Like |Link to Comment
  • The Trouble May Just Be Starting For Wynn Resorts [View article]
    Yesterday you were trashing MPEL, just one day later Wynn. Almost word for word the exact same arguement and charts.
    SA should not allow such low standards. Further this guy "supposedly" is involved with a hedge fund and if he is spending time here trying to get page views he can't be to succesful and one must suspect that with 2 articles in a row hitting the casino stocks maybe his fund or a friends is shorting these stocks?
    Finally where was this guy when Wynn, MPEL etc., was 250 a share?
    Casino stocks may go lower, but i am a buyer here at these levels. I bought all the way down in 2008-09 and made money on the way up.
    when the casino stocks turn, they fly and it is tough to get back in...
    Apr 1, 2015. 11:46 AM | 5 Likes Like |Link to Comment
  • Melco Crown Could Still See Meaningful Downside [View article]
    yet another nobody who really should have written this article when MPEL was 47 or so not after a 50% decline.
    The slightest upside surprise in Macau sends Wynn, LVS, MPEL & MGM up substantially as most of the negative news is priced in.
    This author is simply behind the curve. Could things get worse? certainly, however the risk/reward is favorable that people should be buyers not sellers....
    Mar 31, 2015. 09:01 AM | 3 Likes Like |Link to Comment
  • Even At $159, Can Wynn Be A Solid Bottom Fish Now? [View article]
    Hi Howard,

    One of the best written casino articles on SA. Because you were at a high level within the industry, it gives you unique insights that many if not most might miss. No analyst will come out with future projections at this point because "they are afraid of there jobs"
    Trying to pick the bottom or top is just a lucky strike. I bought today and will continue buying wynn on any negative news.
    No one ever knows when the turn will occur but my experience tells me that you have to be in the game, maybe early but better to be early than too late. Wynn is definately the best out there. depending on the market i see Wynn at 500 bucks a share in the next few years.
    Thanks for a great well written article...
    Feb 25, 2015. 11:31 AM | 1 Like Like |Link to Comment
  • Israeli Biomed-Tech Companies Present Investment Opportunities [View article]
    Dr.Goldmeier,

    Thank you for a well written informative article. Unfortunately the above posters are anti sematic anti everything Israel and most likely Muslim jihad sympathizers.

    I've been in BLRX since last summer and they have many upcoming catalysts.. The analysts have next year forecast @ .36 profit on 85 million in revs which would make this a 10 bagger maybe more. The ph 3 with bellophon is due 4q which would trigger a 40 million payment if successful.

    They have 40 million cash and no debt with a strong pipeline-it is my number 1 biotech pick. If you can handle the volatility the risk/reward is very strong..
    Apr 9, 2014. 12:53 PM | 4 Likes Like |Link to Comment
  • BioLineRx: Extremely Undervalued Company With Multiple Catalysts In 201 [View instapost]
    Shalom Nir,

    A well written article and I would like to add a few points. I think that BLRX represents the possibility of a 10 bagger potential for this year (10 bagger meaning 10 x or 1000% potential)

    One of the analysts has raised the 2015 revenue to 85 million and a profit of .36 cents a share-the aforementioned alone would push this to an 800 million company along with their rich pipeline.
    Certainly everything has to hit to get their. Here is a wildcard with a very very small chance but you never know. Andromeda was recently sold back to Clal from Teva -Clal said they were in talks to sell the diabetes franchise, shortly thereafter BLRX did the capital raise? What are your thoughts on this Nir?
    IF BLRX got the rights for this it would propel the stock 200% in 1 day maybe more.
    Toda Roba
    Mar 28, 2014. 09:25 AM | 1 Like Like |Link to Comment
  • BioLineRx Offers A Wide Range Of Potential Catalysts At An Affordable Valuation [View article]
    I have been in this stock since July and from what I have read the 40 million goes directly to BLRX's bottom line.
    BLRX is then paid royalties between 11%-15% world wide and has rights to everything sold in Israel.
    I do not know the exact structuring, however this would be a huge game changer for BLRX.
    They have so many catalysts between now and the 4th q that it will not stay at these levels for too long.
    Also interesting was that 2 days ago a 13 was filed with the sec Albert Friedberg bought 1.5 million worth of the offering-the others have not come forward as of yet-
    They seem to have a lot of things cooking in the kettle - their Leukemia drug seems like a game changer also..
    Mar 12, 2014. 11:56 AM | 1 Like Like |Link to Comment
  • BioLineRx Offers A Wide Range Of Potential Catalysts At An Affordable Valuation [View article]
    BLRX is one of the most undervalued biotech's period. Certainly some major players bought on the offering-Amazing that the 24 million was gobbled up and they most definitely could have sold more.

    So many catalysts forthcoming on this gem. Rick Berger-they are scheduled to receive 40 million from Bellopharm sometime in the 3rd or 4th quarter based on the completion of ph 3 - this along with the other catalysts, if successful in my opinion push this up 500% - 1000% is a reasonably short time frame.

    Management seems to be making the right moves and 2 new board of directors from the USA were recently elected-all in all I like the company and the odds risk/reward profile..
    Mar 12, 2014. 09:28 AM | 3 Likes Like |Link to Comment
  • Following Smart Money: Baker Brothers LLC Investments In 2013 And Beyond [View article]
    Scott,

    You are right. The Baker brothers have a terrific record most recently. The problem becomes that now everyone will start following them and the fantastic run will slowly become mediocre.

    It would be similar to lets say a commodity going in one direction and then all of the trend followers hop on board only to see the trend reverse.

    Over time this will slow the results down and/or when YOU buy they sell syndrome will occur..
    Dec 20, 2013. 01:46 PM | Likes Like |Link to Comment
  • Will Apoptosis Succeed Where Other Cancer Treatments Haven't? Three Companies Trying [View article]
    MVDolphin,

    Thank you kindly for sharing your personal battle with Cancer. Your courage is inspiring and I wish you the very finest in the years ahead..
    Nov 6, 2013. 06:41 PM | Likes Like |Link to Comment
  • Will Apoptosis Succeed Where Other Cancer Treatments Haven't? Three Companies Trying [View article]
    Would some of the sharp readers please kindly let me know of a SINGLE company with a valuation of up to 2 BILLION that has a pipeline as deep and promising as Bioline RX which has a market cap of 60 MILLION.
    I copied and pasted from their site.

    The BioLineRx pipeline is generated by systematically identifying, validating and in-licensing therapeutic candidates with advantages over current therapies or which address unmet medical needs.

    Over 2,000 compounds have already been systematically screened and evaluated, of which over forty commenced development.

    Today 12 compounds are actively being developed, including seven in clinical stages.

    Clinical
    BL-1040 AMI (CE Mark Registration Trial)

    BL-5010 Skin lesions (Phase I/II complete)

    BL-7040 Inflammatory Bowel Disease ( Phase II)

    BL-8040 Acute myeloid leukemia & other hematological cancers (Phase II)

    BL-1021 Neuropathic Pain (Phase I trial)

    BL-8020 Hepatitis C (HCV)

    BL-1020 Schizophrenia (Phase II/III study discontinued following interim analysis; awaiting complete analysis of unblinded study data)
    Pre-clinical

    BL-7010 Celiac Disease

    BL-7060/EDP29 Inflammatory diseases

    BL-8030 Hepatitis C (HCV)

    BL-9010 Severe allergies/asthma

    **And their early development program of which this week they announced that number 10 is now in clinical


    The goal of an EDP project is to accumulate sufficient in vivo data to facilitate entry into BioLineRx’s pipeline. Projects that enter BioLineRx's pipeline receive full funding and accelerated preclinical and clinical development.

    EDP candidates must be patentable, novel therapeutics, addressing a large unmet medical need. The therapeutic should have a well thought-out mechanism of action, backed by high quality research and scientific rigor.

    For more information: EDP@BioLineRx.com

    Current EDP Pipeline

    EDP 10 represents a family of molecules that inhibit the Natural Killer (NK) receptor NKp46. NKp46 has been linked to type I diabetes and inhibition of this receptor was shown to prevent the development of type I diabetes in animal models. The goal of this project is to identify a specific NKp46 inhibitor and to assess its activity in animal models of type I diabetes.
    Inventors: Prof. Ofer Mandelboim ( Hebrew University of Jerusalem) and Prof. Angel Porgador (Ben Gurion University of the Negev)


    EDP 21 is a novel, recombinant mutant of the human Leptin hormone which acts as a leptin agonist. EDP 21 is intended to assist in weight loss diabetes.
    Inventors: Prof. Arieh Gertler and Dr. Eran Elinav


    EDP 25 is a project for developing inhibitors of the Rel proteins which enable bacteria to adapt to environmental changes. These Rel inhibitors have potential as novel antibacterial agents that would disrupt the survival mechanisms in bacteria.
    Inventor: Prof. Gad Glazer (Hebrew University of Jerusalem)

    EDP 26 is a project for developing molecules targeting the voltage sensor of Kv7.4, Kv7.5 and TRPV1 channels for the treatment of human asthma.
    Inventor: Prof. Bernard Attali (Tel Aviv University)

    EDP 31 is a selective inhibitor of PACE-4, a proteolytic enzyme involved in the processes of tumor progression and invasion. Through careful molecular design and pharmacological optimization, this new compound was shown to have significant growth inhibitory effects on tumor cells lines and in mouse models. It is being developed to treat various cancers that are dependent on the activity of PACE-4. Inventor: Prof. Robert Day, Insitut de Pharmacologie de Sherbrooke, Quebec, Canada


    EDP 32 is an alpha-synuclein derived peptide, which inhibits alpha-synuclein aggregation for the treatment of Parkinson's Disease. Inventors: Prof. Ehud Gazit and Dr. Ronit Shaltiel-Karyo (Tel Aviv University)

    EDP 34 is a small molecule which regulates the opioid-induced glial activation by targeting the critical TLR4/MD-2 complex formation, thus preventing morphine binding to TLR4 receptor in glia, resulting in enhanced analgesic effect. EDP 34 is being developed for the treatment of neuropathic pain and scleroderma. Inventors: Prof. Linda R. Watkins and Prof. Hang Hubert Yin (University of Colorado at Boulder)

    October 23, 2013 Latest Press Releases
    BioLineRx Announces In-Licensing of BL-9020,for Treatment of Type 1 Diabetes



    Oct 26, 2013. 06:59 AM | 1 Like Like |Link to Comment
  • Will Apoptosis Succeed Where Other Cancer Treatments Haven't? Three Companies Trying [View article]
    Hi Andreas,

    Thank you for an intelligent, well written piece. I am not familiar with the other 2 company's however am familiar with Bioline RX.

    A slight correction, Bioline has said that there will be interim results on 8040 in November and completed phase 2 results in Feb I believe.
    8040 recently granted orphan status is supposed to be a real stunner as it has many more ramifications than AML and reportedly is much more active than Mozabil by Sanofi-The British journal of Hematolgy did a piece on 8040 as well
    Here is a quote by a Roth analyst last week

    “BL-8040 is the real deal and it is very promising,” Robert Hazlett, analyst at Roth, said by phone from New York about BioLine’s cancer drug yesterday. “Currently, Sanofi has a product called Mozobil which is similar to BL-8040 but BioLine’s drug is much more active and will likely be considered more broadly by regulators. Mozobil is successful but BL-8040 could be much bigger.” Mozobil brought in net sales of $130.3 million in 2012, Sanofi (SNY) said in its latest half-year report.

    The market cap for Bioline is 60 million and they have 7 drugs in clinical-5 in pre clinical and 10 or so in early development.
    Can you name a company with a market cap up to 1 billion that has that? I am amazed at how much they accomplish and I am holding onto this as it has the potential of a 10 or 20 bagger imo..
    Oct 25, 2013. 12:11 PM | 2 Likes Like |Link to Comment
  • Analysis Of Vical's Allovectin-7: Best Results Ever In A Melanoma Phase 3 Trial [View article]
    I do not always agree with Mr. Fuerstein, however you must respect his opinion-he will not always be right like all of us. On this one I do agree with Mr. Fuerstein however.

    This article leaves much to be desired. obviously he is painting the siren song with green-remember people are selling into the rally-who is selling you must ask yourself?

    Fake outs and deception are common on wall street and if this stock is a 100 buck a share stock-WHY has not a big pharma with the sharpest minds in the world bought this company on the cheap?
    With all this talk of 100 bucks per share will lead many to the holy trail of tears.
    This article is suspect in many ways-beware..........
    Jul 31, 2013. 04:41 AM | 8 Likes Like |Link to Comment
  • Dendreon Analysts Getting Very Skeptical [View article]
    Ladies and Gents,

    Please remember that this loser is NOT A DR OR PHYSICIAN-he is simply shorting the stock and/or working for a hedge that is up to their ears in shorting the stock.

    Anyone can make up a name with a nice backround and of course it sounds very nice that a "Dr" would spend so much time-just so much time knocking down a biotech company.

    No real Dr and I repeat no real Dr. has so much time to write up long flowery stories trying to get YOU to SELL.

    This guy is most likely operating from his basement.

    Keep the aforementioned in mind when reading his long breathy statements designed to >>get YOU to sell<<

    Blackhawk
    May 28, 2013. 05:29 PM | 1 Like Like |Link to Comment
COMMENTS STATS
69 Comments
115 Likes